ESR1 and breast cancer: At diagnosis, around 15% of ER+ breast cancers exhibit a concurrent human epidermal growth factor receptor 2 (HER2) gene-amplification, such that approximately 10% of all breast cancers are ER+/HER2+ (Dodson et al. 2018).